Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Marinus Pharma CS (MRNS)

Marinus Pharma CS (MRNS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 78,556
  • Shares Outstanding, K 54,934
  • Annual Sales, $ 30,990 K
  • Annual Income, $ -141,410 K
  • 60-Month Beta 1.12
  • Price/Sales 2.51
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade MRNS with:

Options Overview Details

View History
  • Implied Volatility 0.00% ( -55.99%)
  • Historical Volatility 63.19%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 372.57% on 04/12/24
  • IV Low 0.00% on 07/26/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 23
  • Volume Avg (30-Day) 78
  • Put/Call OI Ratio 0.20
  • Today's Open Interest 4,357
  • Open Int (30-Day) 12,994

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.59
  • Number of Estimates 6
  • High Estimate -0.54
  • Low Estimate -0.68
  • Prior Year -0.61
  • Growth Rate Est. (year over year) +3.28%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1000 +30.00%
on 06/28/24
1.5400 -7.14%
on 07/16/24
+0.1700 (+13.49%)
since 06/26/24
3-Month
1.1000 +30.00%
on 06/28/24
1.7700 -19.21%
on 05/08/24
+0.0250 (+1.78%)
since 04/26/24
52-Week
1.1000 +30.00%
on 06/28/24
11.2600 -87.30%
on 01/08/24
-8.1900 (-85.14%)
since 07/26/23

Most Recent Stories

More News
Marinus Pharmaceuticals: Q1 Earnings Snapshot

Marinus Pharmaceuticals: Q1 Earnings Snapshot

MRNS : 1.4300 (+1.06%)
Marinus Pharmaceuticals: Q4 Earnings Snapshot

Marinus Pharmaceuticals: Q4 Earnings Snapshot

MRNS : 1.4300 (+1.06%)
Marinus Pharmaceuticals: Q3 Earnings Snapshot

Marinus Pharmaceuticals: Q3 Earnings Snapshot

MRNS : 1.4300 (+1.06%)
Marinus Pharmaceuticals: Q2 Earnings Snapshot

Marinus Pharmaceuticals: Q2 Earnings Snapshot

MRNS : 1.4300 (+1.06%)
Marinus Pharmaceuticals: Q1 Earnings Snapshot

Marinus Pharmaceuticals: Q1 Earnings Snapshot

MRNS : 1.4300 (+1.06%)
Marinus Pharmaceuticals to Present at Upcoming Investor Conferences

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that management will present...

MRNS : 1.4300 (+1.06%)
Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2023 Financial Results on May 11, 2023

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial...

MRNS : 1.4300 (+1.06%)
Marinus Pharmaceuticals Appoints Marvin H. Johnson, Jr. to its Board of Directors

Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the appointment of Marvin H....

MRNS : 1.4300 (+1.06%)
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Marinus Pharmaceuticals, Inc . (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards...

MRNS : 1.4300 (+1.06%)
Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone in the Treatment of Lennox-Gastaut Syndrome

Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the U.S. Food and Drug Administration...

MRNS : 1.4300 (+1.06%)

Business Summary

Marinus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It is focused on developing and commercializing therapeutics for the treatment of epilepsy and other targeted neurological, behavioral and psychiatric disorders. The Company offers Ganaxolone which has completed Phase II clinical...

See More

Key Turning Points

3rd Resistance Point 1.5233
2nd Resistance Point 1.4967
1st Resistance Point 1.4633
Last Price 1.4300
1st Support Level 1.4033
2nd Support Level 1.3767
3rd Support Level 1.3433

See More

52-Week High 11.2600
Fibonacci 61.8% 7.3789
Fibonacci 50% 6.1800
Fibonacci 38.2% 4.9811
Last Price 1.4300
52-Week Low 1.1000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar